Collectively, this study uncovers a novel mechanism in glioblastoma (GBM) involving Smad1 exploiting p300 to induce hypoacetylation of p53, resulting in its own acetylation and promotion of oncogenic effects. Here, EP300 is linked to glioblastoma.